APOBEC3C‐Mediated NF‐κB Activation Promotes Malignant Progression of Gliomas
Immunity, Inflammation and Disease · 2025
DOI: 10.1002/iid3.70224 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2025. Verfasst von Chao Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The Affiliated Chuzhou Hospital of Anhui Medical University, The First People's Hospital of Chuzhou, Chuzhou, China. Hauptthemen laut MEDLINE: Glioma, NF-kappa B, Cytidine Deaminase, Brain Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was supported by the Scientific Research Foundation of the Education Department of Anhui Province (Grant No. 2024AH040093); Chuzhou Science and Techn….
Abstract (Originalsprache)
Objective
To analyze the clinicopathological features, immunological characteristics, and prognostic value of APOBEC3C in gliomas, and to verify the specific mechanism by which it mediates the malignant progression of gliomas. Methods mRNA‐seq data from 693 glioma patients in the CGGA database and 697 glioma patients in the TCGA were analyzed, respectively. In addition, single‐cell sequencing data were obtained from the CGGA database. Bioinformatics methods were applied to reveal the possible mechanisms of APOBEC3C‐mediated malignant progression of gliomas. Moreover, western blot, transwell, and cell‐scratch assays were used to explore the potential mechanisms of APOBEC3C‐mediated glioma invasion and migration.
Results
APOBEC3C was enriched in malignant glioma subtypes and was a potential biomarker for mesenchymal subtypes in glioma patients. It was closely associated with glioma inflammation and immunity. Additionally, APOBEC3C is a potential independent prognostic factor for glioma, and inhibition of APOBEC3C expression can suppress the EMT process in glioma cells through the NF‐κB signaling pathway.
Conclusion
APOBEC3C is a potential biomarker for glioma patients. It is closely related to the clinicopathology of glioma and may be a potential immunotherapy target for glioma patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, The Affiliated Chuzhou Hospital of Anhui Medical University, The First People's Hospital of Chuzhou, Chuzhou, China.
- Health Examination Center, The Affiliated Chuzhou Hospital of Anhui Medical University, The First People's Hospital of Chuzhou, Chuzhou, China.
ORCID-Profile: Chao Zhang
Förderung
- This work was supported by the Scientific Research Foundation of the Education Department of Anhui Province (Grant No. 2024AH040093); Chuzhou Science and Techn…
Zitieren
APA
Zhang, C., Yang, T., Tang, Y., Yu, D., Hou, S., Lin, N., & Li, Q. (2025). APOBEC3C‐Mediated NF‐κB Activation Promotes Malignant Progression of Gliomas. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70224
Vancouver
Zhang C, Yang T, Tang Y, Yu D, Hou S, Lin N, et al. APOBEC3C‐Mediated NF‐κB Activation Promotes Malignant Progression of Gliomas. Immunity, Inflammation and Disease. 2025. doi:10.1002/iid3.70224
BibTeX
@article{Zhang2025,
author = {Zhang, Chao and Yang, Tao and Tang, Yuhang and Yu, Dong and Hou, Shiqiang and Lin, Ning and Li, Qun},
title = {APOBEC3C‐Mediated NF‐κB Activation Promotes Malignant Progression of Gliomas},
journal = {Immunity, Inflammation and Disease},
year = {2025},
doi = {10.1002/iid3.70224}
}
EUVIMED